Repurposing of the small-molecule adrenoreceptor-inhibitor carvedilol for treatment of the fibrotic lung
Herein, carvedilol demonstrated significant anti-fibrotic effects on human lung fibroblasts <i>in vitro</i>, thus presenting great potential as an anti-IPF treatment. In addition, miR-21 was validated as a secreted pro-fibrotic biomarker in the <i>ex vivo</i> PCLS model.
Authors
- Andreas Pich (ORCID: https://orcid.org/0000-0001-8444-0940)
- Patrick Zardo (ORCID: https://orcid.org/0000-0003-4003-4945)
- Lavinia Neubert (ORCID: https://orcid.org/0000-0003-4130-4185)
- Angelika Pfanne
- K. E. Schmidt (ORCID: https://orcid.org/0000-0002-1597-9835)
- Christopher Werlein (ORCID: https://orcid.org/0000-0002-7694-4257)
- Jan Fiedler (ORCID: https://orcid.org/0000-0002-8855-2883)
- Maria C. Jordan (ORCID: https://orcid.org/0000-0001-5272-2185)
- Maximilian Fuchs (ORCID: https://orcid.org/0000-0002-8099-9541)
- L. Willmer
- Annette Just
- Thomas Thum
Institutions
- Medizinische Hochschule Hannover (DE)
- Fraunhofer Institute for Toxicology and Experimental Medicine (DE)
- Fraunhofer-Gesellschaft (DE)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-05-22
- DOI
- https://doi.org/10.3389/fphar.2025.1534989
- Citations
- 2
- Primary Topic
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Type
- article
- Field-Weighted Citation Impact
- 3.04